Golidocitinib for blood side effects from lung cancer immunotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, golidocitinib, to treat severe low blood cell counts caused by immunotherapy in people with advanced lung cancer. It aims to help your blood recover so you can continue cancer treatment and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer or extensive-stage small cell lung cancer that has spread.
- You have severe low blood cell counts (white blood cells, neutrophils, platelets, or hemoglobin) caused by immunotherapy, and these have not improved with standard treatments like steroids or growth factors.
- You have not had cancer progression in the last 2 weeks and are in generally good health (ECOG score 0-2).
- You do not have certain gene changes (driver mutations) that would allow targeted therapy.
- If you have brain metastases, they must be stable and you must not need steroids or seizure medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new pill (golidocitinib) combined with an immunotherapy drug for people with advanced non-small cell lung cancer that has grown despite previous treatment. It may offer a new option for those who have already tried standard treatments.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
Hear when a new IrAE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.